Partheen Karolina, Levan Kristina, Osterberg Lovisa, Claesson Ingela, Fallenius Ghita, Sundfeldt Karin, Horvath György
Department of Oncology, University of Gothenburg, Gothenburg, Sweden.
Int J Cancer. 2008 Nov 1;123(9):2130-7. doi: 10.1002/ijc.23758.
The mortality rate for patients with ovarian carcinomas is high and the available prognostic factors are insufficient. The use of biomarkers may contribute to better prediction and survival for these patients. We aimed to study the gene and protein expressions for 7 potential biomarkers, to determine if it is possible to use them as prognostic factors. Genes selected from our previous microarray analysis (2006), CLU, ITGB3, TACC1, MUC5B, CAPG, PRAME and TROAP, were analyzed in 19 of the tumors with quantitative real-time polymerase chain reaction (QPCR). We found that CLU and ITGB3 were more expressed in tumors from survivors and PRAME and CAPG were more expressed in tumors from deceased patients. None of the other 3 genes were significantly differently expressed. The protein expressions of CLU, ITGB3, PRAME and CAPG were analyzed in 43 of the tumors with western blot for semiquantitative analysis. We established that the mRNA and protein expressions correlated and that all 4 proteins were significantly differently expressed. Further, immunohistochemistry (IHC) was used to localize the expression of the proteins in the tumor samples. According to our results, the 4 biomarkers CLU, ITGB3, PRAME and CAPG may be used as prognostic factors for patients with stage III serous ovarian adenocarcinomas.
卵巢癌患者的死亡率很高，且现有的预后因素并不充分。生物标志物的应用可能有助于更好地预测这些患者的病情及生存情况。我们旨在研究7种潜在生物标志物的基因和蛋白表达情况，以确定是否有可能将它们用作预后因素。从我们之前（2006年）的微阵列分析中选取的基因CLU、ITGB3、TACC1、MUC5B、CAPG、PRAME和TROAP，采用定量实时聚合酶链反应（QPCR）在19个肿瘤中进行了分析。我们发现，CLU和ITGB3在存活患者的肿瘤中表达较高，而PRAME和CAPG在死亡患者的肿瘤中表达较高。其他3个基因均无显著差异表达。采用蛋白质印迹法对43个肿瘤中的CLU、ITGB3、PRAME和CAPG的蛋白表达进行了半定量分析。我们确定mRNA和蛋白表达具有相关性，且所有4种蛋白均有显著差异表达。此外，采用免疫组织化学（IHC）法对肿瘤样本中蛋白的表达进行定位。根据我们的结果，CLU、ITGB3、PRAME和CAPG这4种生物标志物可作为III期浆液性卵巢腺癌患者的预后因素。
